High Point biopharmaceutical company unlocks potential treatment for diabetes

A study published this week by High Point-based biopharmaceutical clinical trials company vTv Therapeutics Inc. (NASDAQ: VTVT) points to a potential new treatment for diabetes. A paper published in the peer-reviewed journal “Science Translational Medicine” details the discovery and development of an investigational, small molecule, liver selective glucokinase, taken by mouth, which showed positive results in a phase 2 study involving patients with type 2 diabetes. CEO and President of VtV…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news